15 November 2022 | News
First standalone vaccine development and GMP manufacturing site in China
Image credit: shutterstock
WuXi Vaccines, a leading global Contract Development and Manufacturing Organisation (CDMO), has entered into an agreement with Harbour BioMed under which Harbour BioMed's manufacturing facility in Suzhou will be transferred to WuXi Vaccines.
The 8,500-square-meter facility includes multiple 250L, 500L and 1000L single-use bioreactors as well as sterile drug-product manufacturing lines. This facility, a new node within WuXi Vaccines global network, will be renovated to provide industry-leading vaccine development and good manufacturing practice (GMP) manufacturing services for its global partners. It will also be WuXi Vaccines' first standalone vaccine development and GMP manufacturing site in China.
Jian Dong, CEO of WuXi Vaccines, commented, "The new facility will expand our capabilities and capacities to better serve our global partners in developing and manufacturing vaccines. We are committed to advancing the accessibility and affordability of high-quality vaccines, with integrated technology platforms that enable our global partners to enhance the well-being of people worldwide."
This agreement on the additional Suzhou facility marks another 2022 milestone for WuXi Vaccines. In July of this year, the company's QC Potency Lab, located in Dundalk, Ireland, received a GMP certificate from Ireland Health Products Regulatory Authority. And in October, the Dundalk vaccine manufacturing facility reached its mechanical completion.